Autologous peripheral blood stem cell transplantation with in vivo T-cell depletion for life threatening refractory systemic lupus erythematosus

Lupus

Volumn 14, Issue 2, 2005, Pages 159-163

  Talaulikar, D ^a   Tymms, K E ^a   Prosser, I ^a   Smith, R ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Haemopoietic stem cell transplant; Systemic lupus erythematosus; Systemic lupus erythematosus disease activity index

Indexed keywords

ALENDRONIC ACID; BROMOCRIPTINE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISOLONE; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADULT; ANTIBIOTIC PROPHYLAXIS; ARTHRITIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CASE REPORT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS ADENOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; STEM CELL MOBILIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION;

ADULT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 14744271784     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2041cr     Document Type: Article

References (13)

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on prognosis studies in SLE. Arthritis Rheum 1992; 35: 630-640.
2. Nossent JC. Course and prognostic value of systemic lupus erythematosus disease activity index in Black Carribean patients. Semin Arthritis Rheum 1993; 23: 16-21.
3. Wallace DJ, Metzer AL. Systemic lupus erythematosus: clinical aspects and treatment. In Koopman WJ ed. Arthritis and allied conditions. Baltimore, MD: Williams and Wilkins, 1997: 1319-1345.
4. Hochberg MC. Epidemiology of systemic lupus erythematosus. In Wallace DJ, Hahn BH eds. Dubois' lupus erythematosus. Baltimore, MD: Williams and Wilkins; 1997: 49-69.
5. Shoenfeld Y and Khamashta M eds. Old treatment - new treatment [special issue]. Lupus 2001; 10: 135-248.
6. Marmont AM. Perspective: immune ablation with stem cell rescue: a possible cure for systemic lupus erythematosus. Lupus 1993; 2: 151-161.
7. Traynor AE, Schroeder J, Rosa RM et al. Treatment of severe lupus erythematosus with high dose chemotherapy and haemopoietic stem cell transplantation: a phase I study. Lancet 2000; 356: 701-707.
8. Tyndall A. Immunoablation and hemopoietic stem cell transplantation for severe autoimmune disease with special reference to severe lupus erythematosus. Lupus 2001; 10: 214-215.
9. Traynor AE, Barr WG, Rosa RM et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Arthritis Rheum 2002; 11: 2917-2923.
10. Karim A, Ahmed S, Siddiqui R, Marder GS, Mattana J. Severe upper airway obstruction from cricoarytenoiditis as the sole presenting manifestation of a systemic lupus erythematosus flare. Chest 2002; 121: 990-993.
11. Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hemopoietic stem cell transplantation. Blood 1998; 92: 3505-3514.
12. Burt RK, Slavin S, Burns WH et al. Induction of tolerance in autoimmune diseases by haemopoietic stem cell transplantation: getting closer to a cure? Blood 2002; 99: 768-784.
13. Tyndall A, Gratwohl A. Consensus statement. Blood and Marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Br J Rheumatol 1997; 36: 390.